An interventional study of Conventional angioplasty and Angioplasty with drug-eluting balloon in Vascular Access Complication, Restenosis, Vascular Graft and Dialysis Related Complications, sponsored by Helsinki University Central Hospital. Completed. Per ClinicalTrials.gov, last updated 2017-06-23.
Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in dialysis fistulae.
Drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. Stenosis and restenosis is a known problem in dialysis fistulae and drug-eluting devices might be beneficial in this field as well.
In the procedure a conventional balloon is passed through the stenosis which is then dilated. After this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon.
The stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. Follow-up will end at 12 months.
Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Angioplasty with drug-eluting balloon
Device: Conventional angioplasty
Angioplasty with conventional balloon
Also known as: PTA
Angioplasty with drug-eluting balloon
Also known as: DEB
TLR
Target lesion revascularization, ie. re-intervention to the same lesion
Time frame: 12 months
Occlusion of access
Any loss of dialysis access due to thrombosis
Time frame: 12 months
Primary assisted patency
Patency after endovascular reintervention due to restenosis or thrombosis
Time frame: 12 months
Death
Time frame: 12 months
No study locations are listed for this record.
Plan to share: No
Ran from Jan 2013 to primary completion in Feb 2017, 49 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Graft Occlusion, Vascular
Helsinki University Central Hospital →